Smart Bombs Against Senescent Cells

Summary: A new nanotechnology enables the selective targeting of senescent cells; in mice, it dramatically improves an age-related lung disease, and makes cancer chemotherapy safer and more effective. Now the scientists behind it have a startup and are headed toward human testing.

Read more...

Human Trials of Two New Rejuvenation Biotechnologies Targeting Alpha-Synuclein

Alpha-synuclein aggregates are a key form of aging damage in the brain, linked to a spectrum of symptoms in Parkinson’s disease beyond the classic motor symptoms. The first amyloSENS-style immunotherapy to clear this pathology out of the brain was advanced into clinical trials by Austrian biotech firm AFFiRiS AG. Now two more such therapies have entered human testing. Although the trials are in their earliest stages, they bring the hope that this rejuvenation biotechnology will begin preventing and reversing Parkinson’s disease and less specific disorders of aging soon.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: